- Home
- HOUR vs BTAI Comparison
HOUR vs BTAI Comparison
Compare HOUR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUR
- BTAI
- Stock Information
- Founded
- HOUR 2015
- BTAI 2017
- Country
- HOUR United States
- BTAI United States
- Employees
- HOUR N/A
- BTAI N/A
- Industry
- HOUR Catalog/Specialty Distribution
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- HOUR Consumer Discretionary
- BTAI Health Care
- Exchange
- HOUR Nasdaq
- BTAI Nasdaq
- Market Cap
- HOUR 63.3M
- BTAI 73.4M
- IPO Year
- HOUR 2022
- BTAI 2018
- Fundamental
- Price
- HOUR $1.52
- BTAI $4.10
- Analyst Decision
- HOUR
- BTAI Strong Buy
- Analyst Count
- HOUR 0
- BTAI 4
- Target Price
- HOUR N/A
- BTAI $40.00
- AVG Volume (30 Days)
- HOUR 22.1K
- BTAI 28.0M
- Earning Date
- HOUR 08-12-2025
- BTAI 08-12-2025
- Dividend Yield
- HOUR N/A
- BTAI N/A
- EPS Growth
- HOUR N/A
- BTAI N/A
- EPS
- HOUR 0.02
- BTAI N/A
- Revenue
- HOUR $138,441,228.00
- BTAI $868,000.00
- Revenue This Year
- HOUR N/A
- BTAI N/A
- Revenue Next Year
- HOUR N/A
- BTAI $597.46
- P/E Ratio
- HOUR $67.34
- BTAI N/A
- Revenue Growth
- HOUR N/A
- BTAI N/A
- 52 Week Low
- HOUR $1.10
- BTAI $1.17
- 52 Week High
- HOUR $6.90
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- HOUR 37.65
- BTAI 50.38
- Support Level
- HOUR $1.46
- BTAI $4.71
- Resistance Level
- HOUR $1.60
- BTAI $5.25
- Average True Range (ATR)
- HOUR 0.09
- BTAI 1.27
- MACD
- HOUR -0.04
- BTAI -0.19
- Stochastic Oscillator
- HOUR 12.88
- BTAI 6.79
About HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.